Ann: HeraBEAT Plus Clinical Trial Study Details, page-37

I’d recommend this as a refresher on the potential here. These guys have a big vision, and they’re doing a great job executing.

The Mayo clinic (a $13 billion USD revenue company) relationship alone has incredible potential. Not only are they a shareholder and very active R&D collaborator, but they introduced the gold standard for home care for low risk pregnancies. OB nest is offered to every single expecting parent with a low risk pregnancy. HeraCare is intended to be the monitoring solution for every one of these OB nest patients.
The company is aiming to support 2 million births this year, and 6-7 million next year. The model is a minimum of $199USD per pregnancy (with reimbursement codes to lower the cost to the consumer). 2,000,000 x $199 is $400m USD ($600m AUD) in revenue.

Add to that the potential of the Hapvida pilot in Brazil, H-Cube engagements in India and KinderHeldin relationship in Germany - three massive markets.

How much of this vision do you think HMD need to execute on before they’re worth more than $30m (double the current market cap). I reckon about 0.25%, or $1.5m AUD revenue would do it.

The risk reward here is simply bonkers. IMO.

DYOR, and have a great weekend all.